Developmental dysphasia in children: a comparison of the effectiveness of two modes of peptidergic nootropic therapy

Zavadenko N.N.; Davydova L.A.; Suvorinova N.Yu.

doi:https://doi.org/10.17116/jnevro202012010138

Zavadenko N.N.

Pirogov Russian National Research Medical University

ORCID: 0000-0003-0103-7422

Davydova L.A.

Pirogov Russian National Research Medical University

Suvorinova N.Yu.

Pirogov Russian National Research Medical University

Developmental dysphasia in children: a comparison of the effectiveness of two modes of peptidergic nootropic therapy

Authors:

Zavadenko N.N., Davydova L.A., Suvorinova N.Yu.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(10): 38‑44

DOI: 10.17116/jnevro202012010138

Read: 5171 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Zavadenko NN, Davydova LA, Suvorinova NYu. Developmental dysphasia in children: a comparison of the effectiveness of two modes of peptidergic nootropic therapy. S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(10):38‑44. (In Russ.)
https://doi.org/10.17116/jnevro202012010138

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)

Использование инфографики авторами научных работ

Close metadata

OBJECTIVE

To study the therapeutic efficacy of two treatment modes of peptidergic nootropic medication cortexin in children with developmental dysphasia aged 3—4 years.

MATERIAL AND METHODS

Ninety-four children with developmental dysphasia were divided into three groups. In group 1 (27 patients), cortexin was administered once a day intramuscularly for 10 days. After this course, the children were not prescribed drug therapy, a second examination was carried out 2 months after the start of treatment. In group 2 (40 patients), two courses of cortexin were administered at 1-month intervals, and the children were also followed up for two months. Control group 3 (27 patients) did not receive medication, but was also followed up for two months. All the parents were provided with recommendations for the stimulation of speech development in children. Before the study and two months later, speech development was assessed with special scales and questionnaires for parents.

RESULTS

The increase ratio of the active vocabulary volume by 2 times or more was observed in group 2 (two courses of cortexin treatment) in 80.0% of patients (significant differences with groups 1 and 3, p<0.001), in 44.4% of group 1 (one course of cortexin), in 22.2% of the control group. Over a two-month period, the increase ratio in the active vocabulary and the number of uttered phrases in group 2 was 2.8 and 4.2 times, in group 1 2.3 and 3.6 times, respectively, in the control group it was only 1.4 and 1.5 times. Furthermore, the volume of active vocabulary in group 2 (42.4±3.6) became significantly larger (p=0.01) than in group 1 (31.7±5.6), although its initial values in group 1 (13.7±1.8) and group 2 (14.9±1.7) were similar.

CONCLUSION

The results of the study confirm the higher effectiveness of two courses of the peptidergic nootropic medication cortexin in the pharmacotherapy of developmental dysphasia in children, aged 3—4 years, conducted over two months, compared with the indication of one treatment course.

Keywords:

developmental dysphasia

children

early intervention

pharmacotherapy

peptidergic nootropic medication

cortexin

Authors:

Zavadenko N.N.

Pirogov Russian National Research Medical University

ORCID: 0000-0003-0103-7422

Davydova L.A.

Pirogov Russian National Research Medical University

Suvorinova N.Yu.

Pirogov Russian National Research Medical University

Received:

27.07.2020

Accepted:

21.08.2020

Close metadata

References:

Law J, Dennis JA, Charlton JJV. Speech and language therapy interventions for children with primary speech and/or language disorders. Cochrane Database of Systematic Reviews. 2017;1:Art. No.: CD012490. https://doi.org/10.1002/14651858.CD012490
Horwitz SM, Irwin JR, Briggs-Gowan MJ, Bosson Heenan JM, Mendoza J, Carter AS. Language delay in a community cohort of young children. J Am Acad Child Adolesc Psychiatry. 2003;42(8):932-940. https://doi.org/10.1097/01.CHI.0000046889.27264.5e
Sachse S, Von Suchodoletz W. Early Identification of Language Delay by Direct Language Assessment or Parent Report? Journal of Developmental & Behavioral Pediatrics. 2008;29(1):34-41. https://doi.org/10.1097/DBP.0b013e318146902a
Hayiou-Thomas M, Carroll J, Leavett R, Hulme C, Snowling M. When does speech sound disorder matter for literacy? The role of disordered speech errors, co-occurring language impairment and family risk of dyslexia. Journal of Child Psychology and Psychiatry. 2016;58:197-205. https://doi.org/10.1111/jcpp.12648
Dodd B. Re-evaluating evidence for best practice in paediatric speech-language pathology. Folia Phoniatrica et Logopaedica. 2020;1-12. Online ahead of print. https://doi.org/10.1159/000505265
Zavadenko NN, Davydova LA, Suvorinova NYu, Khondkaryan GSh. Potential of peptidergic nootropic therapy in developmental dysphasia in children. S.S. Korsakov Journal of Neurology and Psychiatry = Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2019;119(11):47-53. (In Russ.). https://doi.org/10.17116/jnevro201911911147
Chutko LS, Livinskaya AM, Nikishena IS, Yakovenko EA, Surushkina SYu. Neroprotection in residual-organic brain damage with specific speech and language disorders manifestations. In: Neuroprotection in acute and chronic cerebral blood circulation insufficiency. Eds. Skoromets A.A., Dyakonov M.M. SPb.: Nauka; 2007. (In Russ.).
Zavadenko NN, Kozlova EV. Nootropic drug therapy for developmental dysphasia in children. Clinical Practice in Pediatrics. 2013;8(5):24-28. (In Russ.).
ICD-10 — The International Classification of Diseases. The Classification of Mental and Behavioral Disorders. Research and Diagnostic Criteria. SPb.: WHO; 1994. (In Russ.).
Volkova LS, Shakhovskaya SN. Speech therapy. 5th ed. M.: Vlados; 2009. (In Russ.).
Gulyaeva NV. Molecular mechanisms of brain peptide-containing drugs: cortexin. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2018;118(10):93-96. (In Russ.). https://doi.org/10.17116/jnevro201811810193
Collisson BA, Graham SA, Preston JL, Sarah Rose M, McDonald S, Tough S. Risk and Protective Factors for Late Talking: An Epidemiologic Investigation. J Pediatr. 2016;172:168-174.e1. https://doi.org/10.1016/j.jpeds.2016.02.020
Vogel JP, Chawanpaiboon S, Moller AB, Watananirun K, Bonet M, Lumbiganon P. The global epidemiology of preterm birth. Best Pract Res Clin Obstet Gynaecol. 2018;52:3-12. https://doi.org/10.1016/j.bpobgyn.2018.04.003
Sansavini A, Guarini A, Justice LM, Savini S, Broccoli S, Alessandroni R, Faldella G. Does preterm birth increase a child’s risk for language impairment? Early Human Development. 2010;86(12):765-772. https://doi.org/10.1016/j.earlhumdev.2010.08.014
Barre N, Morgan A, Doyle LW, Anderson PJ. Language abilities in children who were very preterm and/or very low birth weight: a meta-analysis. The Journal of Pediatrics. 2011;158(5):766-774.e1. https://doi.org/10.1016/j.jpeds.2010.10.032
Zimmerman E. Do Infants Born Very Premature and Who Have Very Low Birth Weight Catch Up With Their Full Term Peers in Their Language Abilities by Early School Age? J Speech Lang Hear Res. 2018;61(1):53-65. https://doi.org/10.1044/2017_JSLHR-L-16-0150
Almost D, Rosenbaum P. Effectiveness of speech intervention for phonological disorders: a randomized controlled trial. Dev Med Child Neurol. 1998;40(5):319-325. https://doi.org/10.1111/j.1469-8749.1998.tb15383.x
Robertson SB, Ellis Weismer S. Effects of treatment on linguistic and social skills in toddlers with delayed language development. J Speech Lang Hear Res. 1999;42(5):1234-1248. https://doi.org/10.1044/jslhr.4205.1234